genlantis产品代理
genlantis产品代理
Genlantis 提供全系列的专业生命科学系统和产品，包括用于基因传递和质粒 DNA 的 GenePORTER® 转染产品、用于传递 siRNA 以抑制哺乳动物细胞中的基因的 GeneSilencer® 试剂、用于优化原代基因转染的 NeuroFECT™ 试剂神经元和 NeuroPure™ 原代神经元细胞。
扫描牛痘蛋白质组以获取抗天花抗原 该项目的主要目标是从 ACAM2000 菌株中产生完整的牛痘蛋白质组，并用它来鉴定免疫原性抗原，以开发诊断、治疗方法以及针对天花的 DNA 或蛋白质亚单位疫苗。合作者包括位于科罗拉多州拉夫兰的 Luis Cantarero-Mycos Research, LLC 博士和德克萨斯州休斯顿贝勒医学院的 Innocent Mbawuike 博士。
筛选具有保护性抗原的完整 TB 蛋白质组 该项目的主要目标是生产完整的 TB 蛋白质组并使用它来鉴定免疫原性候选物，以开发针对结核病的诊断、治疗和 DNA 或蛋白质亚单位疫苗。合作者包括博士。 John Belisle 和 Ian Orme，科罗拉多州立大学兽医学院，柯林斯堡，CO。
转录活性 PCR 以改进 DNA 疫苗 该项目的主要目标是增强我们在第一阶段拨款 (R43 AI47641-01) 中开发的技术，以筛选免疫原性疟疾抗原，以开发用于诊断、治疗和 DNA 或蛋白质亚单位疫苗的候选疫苗。疟疾。合作者是马里兰州 Silver Spring 海军医学研究中心 (NMRC) 的 Denise Doolan 博士。
Genlantis, a division of Gene Therapy Systems, Inc. is located in San Diego, California. Genlantis designs, develops and commercializes biological reagents for life scientists worldwide. The Company is focused on the development of protein expression systems within proteomics as well as efficient delivery technologies for both in vitro and in vivo applications.
Genlantis offers a comprehensive line of specialty life science systems and products that include the GenePORTER® transfection products for gene delivery and plasmid DNA, GeneSilencer® reagent useful in the delivery of siRNA for gene suppression in mammalian cells, NeuroFECT™ reagent
for optimized transfection of primary neurons, and NeuroPure™ primary neuronal cells.
Scanning the Vaccinia Proteome for Anti Smallpox Antigens The major goal of this project is to produce the complete vaccinia proteome from ACAM2000 strain, and use it to identify immunogenic antigens to develop diagnostics, therapeutics and a DNA or protein subunit vaccine against smallpox. Collaborators include Dr. Luis Cantarero-Mycos Research, LLC, Loveland, CO, and Dr. Innocent Mbawuike, Baylor College of Medicine, Houston, TX.
Screening the Complete TB Proteome for Protective Antigens The major goal of this project is to produce the complete TB proteome and use it to identify immunogenic candidates to develop diagnostics, therapeutics and a DNA or protein subunit vaccine against tuberculosis. Collaborators include Drs. John Belisle and Ian Orme, Colorado State University -College of Veterinary Medicine, Fort Collins, CO.
Transcriptionally Active PCR to Improve DNA Vaccines The major goal of this project is to enhance the technology developed in our Phase 1 grant (R43 AI47641-01) to screen immunogenic malaria antigens to develop candidates for diagnostics, therapeutics and a DNA or protein subunit vaccine against malaria. Collaborator is Dr. Denise Doolan, Naval Medical Research Center (NMRC), Silver Spring, MD.
